tiprankstipranks
Cipher Pharmaceuticals’ Revenue Soars After Natroba Acquisition
Company Announcements

Cipher Pharmaceuticals’ Revenue Soars After Natroba Acquisition

Story Highlights

Cipher Pharmaceuticals (TSE:CPH) has released an update.

Don't Miss Our Christmas Offers:

Cipher Pharmaceuticals reported significant growth in the third quarter of 2024, with total revenue surging by 71% to $10.4 million, driven by the successful acquisition of the Natroba business and strong Epuris sales. The acquisition has also boosted the company’s gross margins, and the new credit facility will support future expansion plans.

For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskCipher Pharmaceuticals Faces Setback but Eyes Growth
TheFlyCipher Pharmaceuticals price target lowered to C$17 from C$19 at Stifel
TipRanks Auto-Generated NewsdeskCipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App